Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”

Stay updated with Hemostasis Today.
-
Nov 21, 2026, 07:18Raising Awareness of Inherited Bleeding Disorders in Women and Girls – World Federation of Hemophilia
-
Nov 21, 2026, 07:10Emmanuel J Favaloro: Latest Publication Posted Online at Seminars in Thrombosis and Hemostasis
-
Nov 21, 2026, 06:52Novel ADAMTS13 Fusion Construct Targets Dual Mechanisms in Immune-Mediated TTP – JTH
-
Nov 21, 2026, 06:38Michael Lichtenberg: Long-Term Results of Venovo Venous Stenting From the Arnsberg Venous Registry
-
Nov 21, 2026, 06:24Platelets Journal: Glycocalicin Accumulation Within Thrombi Reveals Species-Specific Mechanisms
-
Nov 21, 2026, 03:45Aref Ghanaatpisheh: The Role of Systemic Inflammation in Preoperative Deep Vein Thrombosis Risk Assessment
-
Nov 21, 2026, 03:43Dimitrios Hatzichristou: Advancing Standardization and Quality Control in Platelet-Rich Plasma Therapy
-
Nov 21, 2026, 03:15Amirabbas Sheykhalo: Silent Mesenteric Ischemia in Portomesenteric Thrombosis
-
Nov 21, 2026, 02:51Ivone Su: Raising Awareness of Venous Thromboembolism